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Abstract
Introduction: This study aimed to assess whether heart fatty acid-binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) 
could be used for the accurate diagnosis of acute myocardial infarction (AMI) in acute coronary syndrome (ACS) patients.
Materials and methods: The study included 108 ACS patients admitted to a coronary unit within 3 h after chest pain onset. AMI was distinguished 
from unstable angina (UA) using a classical cardiac troponin I (cTnI) assay. H-FABP and GPBB were measured by ELISA on admission (0 h) and at 3, 6, 
12, and 24 h after admission; their accuracy to diagnose AMI was assessed using statistical methods.
Results: From 92 patients with ACS; 71 had AMI. H-FABP and GPBB had higher peak value after 3 h from admission than cTnI (P = 0.001). Both mar-
kers normalized at 24 h. The area under the receiver operating characteristic curves was signifi cantly greater for both markers in AMI patients than in 
UA patients at all time points tested, including admission (P < 0.001). At admission, the H-FABP (37%) and GPBB (40%) sensitivities were relatively 
low. They increased at 3 and 6 h after admission for both markers and decreased again after 24 h. It was 40% for H-FABP and approximately 2-times 
lower for GPBB (P < 0.01). In AMI patients, both biomarkers had similar specifi cities, positive- and negative-predictive values, positive and negative 
likelihood ratios, and risk ratios for AIM.
Conclusion: H-FABP and GPBB can contribute to early AMI diagnosis and can distinguish AMI from UA.
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Introduction
In interventional cardiology with stent revascular-
ization, which localizes myocardial necrosis and 
decreases the possibility for ischaemic bias, it is 
very important to have reliable early biomarkers of 
myocardial cell injury. As a diagnostic tool, bio-
markers could enable appropriate risk stratifi ca-
tion for the increasing number of patients admit-
ted to hospital with acute coronary syndrome 
(ACS) (1). It is accepted that acute myocardial in-
farction (AMI) refers to the death of cardiac myo-
cytes because of prolonged ischemia that is in 
contrast to unstable angina (UA) in which the ne-
crosis of cardiomyocytes does not occur (1-3). The 
routine introduction of cardiac troponins in the 
laboratory has radically improved the diagnosis of 
AMI, because only necrotic cardiomyocytes re-
lease these proteins into the blood (1,2). Troponins 
are more specifi c and sensitive than the traditional 
cardiac enzymes, such as creatine kinase (CK) and 
its isoenzyme MB (CK-MB) and myoglobin (4). How-
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ever, cardiac troponin I (cTnI) can only be detected 
at least 4–6 h after AMI onset; moreover, its levels 
do not peak until 12 hours after onset (detected 
using classical cTnI enzyme linked immunoassays) 
(5). Consecutive cTnI measurements in combina-
tion with the use of reference change value repre-
sent a more sensitive tool for AMI detection and 
allow the evaluation of AMI at low troponin con-
centrations (6). There is no basic diff erence be-
tween cTnI and cardiac troponin T (cTnT) with re-
spect to their ability to diagnose AMI; diff erences 
most frequently arise from variations in inclusion 
criteria, sampling patterns, or from the use of as-
says with diff erent diagnostic cut-off s (1). At 2 h af-
ter AMI presentation, high-sensitivity cTnT assays 
are better diagnostic tools than cTnI assays (7). In 
addition, cTnT assay has a better prognostic ability 
than a conventional assay (7). However, the cTnT 
assay probably refl ects early cTnT release from an 
increasingly permeable myocardial cell membrane 
rather than from a clinically threatening AMI (8). 
Thus high-sensitivity cTnT assay is probably not 
suitable for distinguishing AMI from UA.
During the last 20 years, many scientifi c groups 
have been searching for diagnostic biomarkers 
other than troponins that can predict ischemic 
myocardial injury (3,4,9-17). Of these, interleukin-6, 
high-sensitivity C-reactive protein and brain natri-
uretic peptide have been extensively validated 
and routinely used (1,3). Heart fatty acid-binding 
protein (H-FABP) (3,4,10-13) and glycogen phos-
phorylase isoenzyme BB (GPBB) (14-16) belong to a 
group of novel biomarkers. H-FABP is a 14.5 kDa, 
small, cytosolic protein that is abundant in the cy-
toplasm of cardiomyocytes, but is present in low 
concentrations in the blood and in tissues other 
than the heart (11). It appears in the blood as early 
as 1.5 h after AMI onset, peaks at approximately 6 
h, and returns to baseline values within 24 h (11). 
However, its signifi cance for the diagnosis and 
prognosis of AMI must be verifi ed in future studies 
before it can be routinely used. Early biomarker 
studies have shown that GPBB is a very sensitive 
cardiac biomarker for early myocardial necrotic cell 
injury, as well as for ischaemia (15,16). GPBB activa-
tion in myocardial ischaemia occurs as a result of 
an increase in glycogen degradation, which releas-
es GPBB into the bloodstream (16). Its possible abil-
ity to discriminate myocardial necrosis from isch-
emia without necrosis is of a major clinical interest 
(1). However, there is still an emerging need for 
earlier and suffi  ciently specifi c cardiac biomarkers 
for ACS diagnosis (3,8,14), with ability to distinguish 
AMI and UA.
The aim of this study was to assess the diagnostic 
accuracy of H-FABP and GPBB in ruling-in the acute 
myocardial infarction in patients with acute coro-
nary syndrome, who were admitted to coronary 
unit within 3 hours after the chest pain.
Materials and methods
Patients
Between January and September 2011, we have 
enrolled a consecutive series of patients with chest 
pain in this cross-sectional study. From total num-
ber of patient, the patients having chest pain for 
longer than 3 hours, having chest pain non-sug-
gestive for ACS, patients who died within 24 hours 
after the admission, patients who were inappro-
priately sampled or refused to participate in the 
study were excluded from the further investiga-
tion. Inclusion criteria for ACS were based on the 
European Society of Cardiology (ESC) guidelines 
on ACS, with patients requiring 2 out of 3 parame-
ters for the diagnosis of AMI (suggestive coronary 
chest pain, electrocardiogram [ECG] changes, and 
a positive cTnI value) (1). In patients with sugges-
tive coronary chest pain with duration ≥ 20 min-
utes and/or ECG changes (new ST elevation at the 
J-point in two contiguous leads with the cut-off  
points: ≥ 0.2 mV in men or ≥ 0.15 mV in women in 
leads V2–V3 and/or ≥ 0.1 mV in other leads, new 
horizontal or down-sloping ST depression ≥ 0.05 
mV in two contiguous leads; and/or T inversion ≥ 
0.1 mV in two contiguous leads with prominent R-
wave or R/S ratio > 1). AMI was diagnosed by de-
tecting the increase and/or decrease in cTnI values 
with at least 1 value above the 99th percentile of 
the upper reference limit (0.2 µg/L) (1). Patients 
with negative cTnI values were diagnosed as hav-
ing UA. All ACS patients (AMI and UA), admitted 
within 3 h from the onset of coronary chest pain to 
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the Coronary Care Unit (CCU) of the Department 
for Internal medicine, University Hospital Rijeka, 
were examined further. Exclusion criteria were 
congenital heart disease, primary cardiomyopathy, 
pre-excitation syndrome, an implanted pacemaker 
or cardioverter defi brillator, acute infection, signifi -
cant renal impairment (estimated glomerular fi ltra-
tion rate [eGF] < 60 mL/min/1.73 m2 or autoim-
mune diseases, and reproductive period in wom-
en. Patients were classifi ed as ‘smokers’ if they had 
smoked more than 10 cigarettes per day for > 1 
year during the last 2 years. Arterial hypertension 
was diagnosed if blood pressure was > 140/90 
mmHg. Hyperlipidaemia was defi ned as total cho-
lesterol concentration > 5 mmol/L, low-density li-
poprotein (LDL) cholesterol levels > 3 mmol/L, 
very-LDL levels > 1.7 mmol/L, and high-density li-
poprotein cholesterol levels of < 1.30 mmol/L for 
women and < 1.03 mmol/L for men (18). Diabetes 
mellitus was defi ned as fasting blood glucose level 
of > 7.1 mmol/L (19). The study protocol conformed 
to the ethical guidelines of the 1975 Declaration of 
Helsinki as refl ected in a priori approval by the in-
stitution’s Human Research Committee. All partici-
pants provided informed consent before partici-
pating in the study.
Methods
Medical examination and patient treatments
During anamnesis and the fi rst medical examina-
tion on admission, age, gender, coronary risk fac-
tors including current blood pressure, previous 
heart disease (AMI, percutaneous coronary inter-
vention, or CABG), and pain initiation-to-admission 
time were examined for each patient. A standard 
12-lead ECG was taken on admission and at 12 and 
24 h after the onset of the acute coronary event. 
Patients were followed up in the CCU during the 
entire investigation. Patients with ACS were treat-
ed according to European guidelines, which were 
relatively similar for all the patients. The treatment 
regimen included a β-blocking agent, an angio-
tensin-converting enzyme inhibitor, statin, and 
acetylsalicylic acid in accordance with the current 
European Heart Association guidelines (1).
Blood sampling
To estimate cTnI, H-FABP and GPBB concentrations, 
blood samples were collected from each patient 
at admission (“0-h” time point) and after 3, 6, 12, 
and 24 h. To determine GPBB concentrations, 3 mL 
of peripheral blood was collected at each time 
point in a heparinised vacutainer (Becton Dickin-
son, Plymouth, UK). Within 30 min after collection, 
the samples were centrifuged at 3000 × g for 10 
min, and plasma was immediately separated and 
frozen at -20 °C. H-FABP and cTnI concentrations in 
serum samples were determined by collecting 3 
mL of blood at the same time points as those for 
GPBB quantifi cation. However, these samples were 
collected in vacutainers without an anticoagulant. 
Blood samples were left to clot for 30 min before 
centrifugation at 3000 × g for 10 min. cTnI was as-
sessed immediately from the serum; the remain-
ing homogenate was aliquoted and frozen imme-
diately at -20 °C for H-FABP testing. All samples (10/
patient) were kept frozen for not more than 6 
months before being tested. Repeated freezing 
and thawing cycles were avoided, and samples 
were tested by ELISA within 1 hour after thawing 
without further dilution. An additional blood sam-
ple (3 mL) was used to analyse glucose and lipid 
concentrations at the time of admission.
Determination of biomarkers
First, patients underwent serial testing with a con-
ventional cTnI assay. The concentrations of cTnI in 
serum samples were analyzed immediately after 
centrifugation on the Dimension RxL (Siemens 
Healthcare Diagnostics, Newark, NJ, USA) by using 
reagents manufactured by the same company (Di-
mension Clinical Chemistry System, Heteroge-
neous Immunoassay Module, and Flex Reagent 
Cartridge). The detection range was between 0.04 
and 40.00 ng/mL, with intra-assay coeffi  cient of 
variation (CV) < 6.85% and inter-assay CV of < 10% 
and a cut-off  value of 0.2 ng/mL (CV < 10%) (20). 
H-FABP concentrations were determined by an 
ELISA test (Hycult Biotechnology, Uden, The Neth-
erlands), with the upper limit of the reference 
range of 5.0 ng/mL. The detection range was be-
tween 0.1 and 25.0 ng/mL (21). The GPBB concen-
trations were determined using the Diacordon 
Biochemia Medica 2012;22(2):225–36
228
Cubranic Z. et al.  H-FABP and GPBB in myocardial infarction
GPBB–ELISA test (Diagenics, Dusseldorf, Germany), 
with the upper limit of the reference range of 7.0 
ng/mL (21,22). According to manufacturer, the de-
tection range was between 3 and 100 ng/mL, with 
intra-assay CV of < 6.85% and inter-assay impreci-
sion CV of < 10.3 ng/mL. The absorbencies of both, 
H-FABP- and GPBB-ELISA tests were measured us-
ing the Microplate reader MRX (Dynex Technolo-
gies, Denkendorf, Germany). All the tests were per-
formed in the Department of Laboratory Diagnos-
tic, University Hospital Rijeka, Rijeka, Croatia. The 
readers of the tests and reference standards were 
highly professionally educated persons, who were 
blind for the results of the other test.
Statistical analysis
Data analyses were performed using the SPSS 15.0 
statistical package for Windows, Version SPSS Inc. 
2006. (Chicago, IL, USA). The concentrations of H-
FABP, GPBB, and cTnI deviated signifi cantly from 
normal distributions (P < 0.05) when measured by 
Kolmogorov–Smirnov tests (part of SPSS 15.0 sta-
tistical package) for patients in both the AMI and 
UA groups in each particular time point tested. 
Therefore, non-parametric tests were used for fur-
ther evaluation of data. A non-parametric Mann–
Whitney U test was used to determine the diff er-
ence between the 2 groups. A P-value of < 0.05 
was considered statistically signifi cant. The chi-
square test was performed for the categorical vari-
ables, with 2-tailed P-values of < 0.05 regarded as 
signifi cant. Continuous variables were presented 
as medians and 25th–75th percentiles, and cate-
gorical variables were presented as percentages. 
The receiver operating characteristic (ROC) curves 
were generated for each enzyme to assess the 
ability of each biomarker to be used as an early in-
dicator of AMI. The area under the ROC curve 
(AUC) was calculated with 95% confi dence interval 
(CI). Sensitivities, specifi cities, positive- and nega-
tive-predictive values, positive and negative likeli-
hood ratios, and risk ratios for AMI were calculated 
for each biomarker to determine its potential to di-
agnose AMI. Risk ratio was calculated from equa-
tion RR = (a / (a+b) / (c / (c+d)), where „a“ repre-
sents really positive, „b“ represents falsely positive, 
„c“ represents falsely negative and „d“ represents 
really negative. A Z-test was used to compare the 
sensitivity and specifi city of H-FABP with GPBB. 
Diff erences in concentrations between the indi-
vidual markers were tested by Wilcoxon test. A rel-
ative increase was expressed as percentage of 
change from the initial state (0-h time point). The 
value obtained by the subtraction of 0-h concen-
tration from the concentrations at 3, 6, 12, or 24 h 
was divided by the value at 0-h time point and 
then multiplied by 100. The power of study was 
calculated on the basis of cTnI values obtained in 
patients with AIM and UA. It accounts 0.845 or 
84.5%, what was acceptable, due to desired statis-
tic power > 80%. The power study was calculated 
using PS Power and Sample size Calculations, Ver-
sion 3.0, January 2009, according the reference 
(23).
Results
Patient characteristics
Out of the 214 patients admitted to the CCU with 
chest pain, 122 patients were excluded from the 
study after anamnesis and physical examination 
(Figure 1). Patients who had experienced chest 
pain for more than 3 h at admission (N = 108) were 
excluded from the study. Of the patients who ex-
perienced chest pain for less than 3 h at the admis-
sion, 14 were excluded from the study because of 
non-suggestive coronary chest pain (N = 7), refusal 
to participate (N = 1), death within 24 h (N = 3), in-
appropriate blood sampling (N = 3) (Figure 1). Pa-
tients with a suggestive coronary chest pain within 
less than 3 h before admission (N = 94) were in-
cluded in the study and cardiac markers were as-
sessed. Patients with outlier concentrations of car-
diac biomarkers (N = 2) were also excluded from 
the study.
The median time from symptom onset to presen-
tation was 2 (1.5-2.5) hours for AMI group and 2 
(1.6-2.6) hours for UA group (Table 1). Patients were 
divided into 2 groups on admission: patients with 
AMI and positive cTnI level (N = 71) and patients 
with UA and negative cTnI level (N = 21), which 
were determined from ECGs and cTnI concentra-
tions (Figure 1). Beside cTnI, in both groups H-FABP 
and GPBB were assessed at the admission.
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The groups did not signifi cantly diff er in age, sex 
and pain-to-admission time (Table 1). In the group 
of UA, hypertension was found in 90.5% of pa-
tients, what was signifi cantly higher when com-
pared to the AMI group (62%, P = 0.028), whereas 
other risk factors such as smoking status, hyperlip-
idemia and diabetes mellitus did not diff er signifi -
cantly (Table 1). Previous myocardial infarction was 
more common in patients with UA then in patients 
with AMI (42.90% vs. 12.70%; P = 0.006), whereas 
both groups of patients had similar percentage of 
percutaneous coronary intervention or coronary 
artery bypass grafting (Table 1).
Cardiac biomarker dynamics
Figure 2 shows cardiac biomarkers concentration 
dynamics and their interaction during the fi rst 24 
h after admission in patients with AMI. At the 0-h 
time point (within 3 h from the onset of AMI), the 
concentrations of H-FABP and GPBB were similar 
and relatively low (P (a) = 0.254, Figure 2A and Fig-
ure 2, Table B); however, the levels of both bio-
markers were higher than those of cTnI (P (b) and 
(c) = 0.001, Figure 2, Table B). In the Figure 2, Table 
214 patients with chest pain
Anamnesis+ physiscal examination
↓
122 patients were excluded:
108 patients having chest pain for > 3 hrs
14 patients having chest pain for < 3 hrs
with following characteristics:
  – 7 patients-non suggestive ACS
  – 1 refused to participate
  – 3 patients died within 24 hours
  – 3 inapropriate blood samples
»O-h« time point
(at presentation)
cTnl + ECG
H-FABP + GPBB
2 patients with outlier 
concentrations of cardiac 
markers were excluded
Positive cTnI level
> 99th percentile
N = 71
Acute myocardial infarction 
cTnI, H-FABP, GPBB at time points:
3, 6, 12 and 24 hours after the admitting
94 patients 
admitted within 3 hours
from symptom onset
Negative cTnI level
< 99th percentile
N = 21
Unstable angina (UA)
FIGURE 1. Recruitment of patients presenting with chest pain 
and results of early measurement of cTnI.
All patients
N = 92
AMI
N = 71
UA
N = 21 P
Age (years) 62 (28-89) 61 (28-89) 65 (39-89) 0.432
Male (%) 68.50 71.80 57.10 0.315
Pain-to-admission time (hours) 2.00 (1.50-2.50) 2.00 (1.50-2.50) 2.00 (1.60-2.60) 0.783
Risk factors
Smoking (%) 39.10 45.10 19.00 0.058
Hypertension (%) 68.50 62.00 90.50 0.028
Hyperlipidaemia (%) 69.60 70.40 66.70 0.953
Diabetes mellitus (%) 31.50 26.80 47.60 0.124
History of CHD
Previous MI (%) 19.60 12.70 42.90 0.006
Previous PCI (%) 10.90 7.00 23.80 0.077
Previous CABG (%) 4.30 2.80 9.50 0.475
CHD - coronary heart disease; AMI - acute myocardial infarction; UA - unstable angina, PCI - percutaneous coronary intervention; CABG - coronary 
artery bypass grafting.
Age is presented as median (min-max) and pain-to-admission time as median (25th-75th percentiles). Diff erences between AMI and UA groups 
were calculated with Mann-Whitney U test or Chi squarred test.
TABLE 1. Characteristics of the whole group of patients enrolled in the study and the particular characteristics of patients with acute 
myocardial infarction and patients with unstable angina.
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cTnl
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Relative increase (%)
Time points
(hours)
H-FABP
(ng/mL)
GPBB
(ng/mL)
cTnI
(ng/mL) P H-FABP GPBB cTnI
0 3.33(1.10-11.01)
5.30
(2.10-13.50)
0.08
(0.02-0.20)
(a) 0.254
(b) 0.001
(c) 0.001
- - -
3 73.54(38.2-110.9)
58.30
(30.2-122.5)
13.79
(3.76-49.09)
(a) 0.788
(b) 0.001
(c) 0.001
2108.41 1000.00 17137.50
6 39.20(19.2-97.26)
36.50
(13.5-94.1)
44.28
(14.6-163.71)
(a) 0.977
(b) 0.003
(c) 0.008
1077.18 588.68 55250.00
12 18.45(5.84-39.90)
17.80
(5.4-47.9)
62.84
(26.9-138.13)
(a) 0.630
(b) 0.001
(c) 0.001
454.05 234.85 78450.00
24 3.93(1.40-10.27)
2.70
(2.0-6.5)
36.20
(17.35-69.3)
(a) 0.306
(b) 0.001
(c) 0.001
18.02 -49.06 45150.00
Data are presented as median (25th-75th percentiles).
FIGURE 2. Average dynamics of H-FABP, GPBB and cTnI in patients with AMI (N = 71) admitted within 3 hours from symptom onset is 
shown graphically (A) and in the table (B). The statistical diff erences (P values) between H-FABP and GPBB (a); H-FABP and cTnI (b); 
GPBB and cTnI (c) are calculated with Wilcoxon test.
A
B
B the level of statistical diff erences (P) between H-
FABP and GPBB are designated as (a); between H-
FABP and cTnI are designated as (b) and between 
GPBB and cTnI are designated as (c). Shortly after 
admission, the concentrations of H-FABP and GPBB 
rapidly increased to equal levels, peaking at 3 h 
(73.54 (38.18–110.99) and 58.30 (30.20–122.50) ng/
mL, respectively) (P (a) = 0.788, Figure 1A and Fig-
ure 2, Table B). In contrast, the increase in cTnI con-
centration was slow during the same time period; 
at 3 h, the cTnI levels were lower than those of H-
FABP and GPBB (P (b) and (c) = 0.001, Figure 2A and 
Figure 2, Table B). However, rapid increase in cTnI 
concentrations was prominent at 6–12 h after ad-
mission, which was accompanied by a correspond-
ing decrease in H-FABP and GPBB concentrations 
(Figure 2A). It resulted in signifi cantly lower con-
centrations of both, H-FABP and GPBB when com-
pared with cTnI at 6 h (P (b) = 0.003 and P (c) = 
0.008) and at 12 h after admission (P (b) and (c) = 
0.001, Figure 2, Table B). The H-FABP and GPBB 
concentrations did not diff er signifi cantly between 
themselves at 6 h (P (a) = 0.97) and at 12h (P (a) = 
0.630). At the 24-h time point, the concentration of 
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cTnI was higher than those of H-FABP and GPBB (P 
(b) and (c) < 0.001), and H-FABP did not signifi cant-
ly diff er from GPBB (P (a) = 0.306, Figure 2, Table B).
Relative increase in H-FABP in patients with AMI is 
particularly high at 3 h after admission and ac-
counts for 2108.41% from the 0-h time point (Fig-
ure 2, Table B). It decreased approximately 2 times 
at 6 h after admission and again doubly reduced 
at 12 h after admission (Figure 2, Table B). GPBB fol-
lowed very similar dynamic, but the relative in-
crease in GPBB was 1000% at 3 h after admission 
(Figure 2, Table B). At 3 h after admission relative 
increase in cTnI was 17137.50%, it increased slowly, 
peaked at 12 h time point, when the relative in-
crease was 78450.00%. After that it slowly de-
creased at 24 h after admission. The concentra-
tions of H-FABP, GPBB and cTnI in patients with UA 
were always bellow their cut off s of 5.0 ng/mL, 7.0 
ng/mL or 0.2 ng/mL, respectively (Table 2).
Receiver operating characteristic curves
Table 2 shows the AUC for H-FABP and GPBB for 
the diagnosis of AMI. At admission, for patients 
having coronary chest pain for < 3 h, the AUC was 
signifi cantly greater for initial H-FABP (0.91; 95% CI 
= 0.85–0.97 and GPBB (0.96; 95% CI = 0.93–1.00 in 
patients with AMI than in patients with UA (P < 
0.001); this remained highly discriminatory for all 
the time points tested (3, 6, 12, and 24 h) (Table 2). 
There appeared to be no diff erence between the 
H-FABP and GPBB ROC curves.
Diagnostic performance of H-FABP and GPBB
In AMI patients, the sensitivities of H-FABP and 
GPBB at admission were rather low (37% and 40%, 
respectively) didn’t diff er signifi cantly (Table 4). 
The sensitivity of H-FABP increased at 3 and 6 h af-
ter admission (99% and 93%, respectively), which 
was statistically similar to the sensitivity of GPBB. 
At the 24-h time point, the sensitivity of H-FABP 
decreased to 40%; however, this was approximate-
ly 2-times higher than the value for GPBB (P < 0.01) 
(Table 4). The specifi city, positive- and negative-
predictive values, positive and negative likelihood 
ratios, and risk ratios for AMI were calculated for 
both biomarkers (Table 3). The overall diagnostic 
accuracy of H-FABP and GPBB did not diff er signifi -
cantly.
Time points (hours)
0 3 6 12 24
H-FABP
(ng/mL)
0.34
(0.1-0.71)
0.4
(0.15-1.71)
0.6
(0.1-1.4)
0.1
(0-0.38)
0.1
(0-0.35)
GPBB
(ng/mL)
0.2
(0-1.55)
1.2
(0.2-4.05)
2,1
(0.45-4.27)
1.23
(0.95-2.05)
0.9
(0-1.65)
cTnI
(ng/mL)
0.02
(0-0.02)
0.02
(0-0.02)
0.01
(0.01-0.1)
0.01
(0-0.02)
0
(0-0.01)
Data are presented as median (25th-75th percentiles).
TABLE 2. Average dynamics of H-FABP, GPBB and cTnI in patients with UA (N =21) admitted within 3 hours from symptom onset.
Biomarker Time points(hours) AUC 95% CI P
H-FABP
0 0.91 0.85-0.97 <0.001
3 0.97 0.92-1.02 <0.001
6 0.96 0.89-1.03 <0.001
12 0.98 0.96-1.00 <0.001
24 0.92 0.86-0.98 <0.001
GPBB
0 0.96 0.93-1.00 <0.001
3 0.93 0.86-0.99 <0.001
6 0.90 0.81-0.98 <0.001
12 0.92 0.85-0.98 <0.001
24 0.90 0.84-0.97 <0.001
CI - confi dence intervals.
TABLE 3. Area under receiver operating characteristic curves 
(AUC) for cardiac biomarkers at the optimal cut off  points (99th 
percentile of the general population) for the diagnosis AMI in 
patients admitted within 3 hours from symptom onset (N =71) 
in respect to patients with unstable angina (N = 21).
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Time points
(hours)
0 3 6 12 24 
H-FABP
Sensitivity 37%(27-49%)
99%
(92-100%)
93%
(85-97%)
77%
(66-85%)
40%
(29-52%)
Specifi city 96%(78-99%)
91%
(71-98%)
95%
(77-99%)
96%
(78-99%)
96%
(78-99%)
Positive predictive value 96%(82-99%)
97%
(90-99%)
99%
(92-100%)
98%
(90-100%)
97%
(83-99%)
Negative predictive value 32%(22-44%)
95%
(76-99%)
80%
(61-91%)
57%
(41-71%)
33%
(23-46%)
Positive likelihood ratio 8.17(1.2-56.8)
10.35
(2.77-38.70)
19.52
(2.88-132.33)
16.97
(2.49-115.66)
8.80
(1.27-61.01)
Negative likelihood ratio 0.66(0.54-0.81)
0.02
(0.00-0.11)
0.07
(0.03-0.17)
0.24
(0.15-0.37)
0.63
(0.51-0.78)
Risk ratio 1.48(1.25-1.75)
19.44
(2.88-131.41)
4.93
(2.25-10.79)
2.32
(1.60-3.35)
1.50
(1.26-1.79)
GPBB
Sensitivity 40%(29-52%)
97%
(90-99%)
86%
(76-92%)
70%
(59-80%)
23%
(15-34%)*
Specifi city 96%(78-99%)
81%
(60-92%)
86%
(65-95%)
95%
(77-99%)
96%
(78-99%)
Positive predictive value 97%(83-99%)
95%
(87-98%)
95%
(87-98%)
98%
(90-100%)
94%
(73-99%)
Negative predictive value 33%(23-46%)
90%
(69-97%)
64%
(46-79%)
49%
(34-64%)
28%
(19-39%)
Positive likelihood ratio 8.80(1.27-61.01)
5.10
(2.11-12.33)
6.01
(2.10-17.22)
14.79
(2.17-100.74)
5.03
(0.71-35.80)
Negative likelihood ratio 0.63(0.51-0.78)
0.04
(0.01-0.14)
0.16
(0.09-0.03)
0.31
(0.21-0.45)
0.81
(0.69-0.95)
Risk ratio 1.50(1.26-1.79)
8.98
(2.42-33.35)
2.67
(1.62-4.40)
1.91
(1.42-2.59)
1.39
(1.21-1.60)
Level of statistical signifi cance *P < 0.01 between sensitivity of H-FABP and GPBB at 24 hours after the admission as calculated with Z-test.
Values in parentheses represent 95% confi dence intervals; h, hours after admission.
TABLE 4. Signifi cance of diagnostic H-FABP and GPBB estimation in patients with AMI admitted within 3 hours from symptom onset 
(N = 71).
Discussion
The ability to distinguish acute ACS patients from 
a very large proportion of patients with cardiac 
pain is a diagnostic challenge, especially for pa-
tients with no clear symptoms, unclear ECG fea-
tures, and/or borderline diagnostic cTnI concentra-
tions (1). Elderly women who have survived a myo-
cardial infarction frequently visit their doctors 
complaining of chest pain and have signifi cantly 
higher mortality rate, target lesion reoclussion 
(3,24), postinfarction refractory anaemia in the 
short term, and AMI in the long term (25,26). Al-
though cardiac troponin is a pivotal marker of 
cardiac ischaemic injury/necrosis (27), a single 
negative cTnI test is not suffi  cient to disregard the 
presence of AMI because of its low sensitivity in 
the fi rst 3 h of chest pain onset (2,3). Our results 
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showing a slow, early increase in cTnI concentra-
tions to above the cut-off  value at the time of early 
patient admission also suggest this. Therefore, re-
peated measurements of cTnI concentrations in 
the period of its higher sensitivity (84.1%) and 
specifi city (93.4%) (28) are required, which com-
prises the subsequent 6–9 h after admission 
(27,28). Accordingly, we noticed a rapid increase in 
cTnI concentrations between 6 and 12 h after ad-
mission. This substantially prolongs the time re-
quired for an accurate diagnosis after the acute 
coronary event and reduces the likelihood of 
achieving high-quality myocardial revasculariza-
tion by primary percutaneous intervention or stent 
implantation (25,29). Recently introduced high-
sensitivity troponin assays are capable of identify-
ing high-risk patients early and more eff ectively, 
providing a reliable and rapid prognosis predic-
tion that enables a fast-track rule-out protocol (3 
h) (1,7). However, higher-sensitivity cardiac tro-
ponin assays rather refl ect the troponin release af-
ter increased permeability of the myocardial cell 
membrane without specifi cally pointing out ne-
crosis, which is a characteristic feature of a clinical-
ly threatening AMI (8). Although cTnT concentra-
tions, measured using high-sensitivity assays, are 
elevated early after the acute coronary event, its 
diagnostic accuracy may be compromised be-
cause levels can also be elevated in many patients 
with stable angina (30,31) and in healthy individu-
als (32), thus weakening its ability to diff erentiate 
between healthy subjects and patients with AMI, 
UA, and stable angina. According to the sensitivity 
of the ELISAs used in our study, both H-FABP and 
GPBB markers were not elevated in the patients 
with UA, which is in contrast to that in patients 
with AMI, and statistically signifi cant diff erences 
were obtained from AUC analysis at all time points 
tested. This emphasizes the signifi cance of H-FABP 
and GPBB in distinguishing UA from AMI, particu-
larly during early ACS with peak sensitivities and 
specifi cities occurring at 3 h after admission. This is 
in contrast to other studies, which suggest that H-
FABP might be a marker for myocardial ischaemia 
even in the absence of necrosis (10). Recently, H-
FABP has been proposed to be an early marker for 
ACS because it is only elevated in AMI patients 
(4,10,17) and appears before the traditional marker 
troponin in 22% patients at presentation (3). 
Wiswanathan et al. (10) confi rmed the prognostic 
value and independent prediction of death by us-
ing elevated H-FABP levels in low- and intermedi-
ate-risk patients with suspected ACS. We advocate 
the use of H-FABP alone or in combination with 
high-sensitivity troponin assays to improve the 
sensitivity of early AMI diagnosis. This is in agree-
ment with the opinion of McCann et al. who de-
clared that assessment of H-FABP within the fi rst 4 
h of symptom onset is even superior to cTnT for 
the detection of AMI (14). Our results show that 
GPBB has very similar average dynamics to H-FABP, 
as reported previously (15). GPBB does not com-
pete with cTnT in terms of sensitivity in AMI pa-
tients (14), especially at the fi rst hour after admis-
sion (33). Its activation in myocardial ischaemia is a 
result of an increased glycogen degradation, which 
results in GPBB release into the bloodstream (15,22) 
and diminishes its diagnostic accuracy to distin-
guish between AMI and UA (33). However, its spec-
ifi city is high and comparable to that of CK-MB (15). 
All humoral biomarkers have been criticized in 
terms of their specifi city. Accordingly, troponin 
concentrations may be increased in patients with 
serious vascular chest pain, non-coronary myocar-
dial injury, skeletal myopathies, or chronic renal 
failure, resulting in incorrect prognosis (1,8). H-
FABP was also criticized for insuffi  cient specifi city, 
owing to its presence in diff erent tissues such as 
the skeletal muscles, liver, adipose tissue, gut, skin, 
kidney, or brain (14). The specifi city of H-FABP can 
be improved using modern assays with no cross-
reactivity (12) and particularly in combination with 
high-sensitivity cTnT assay. GPBB isoforms are pres-
ent in the brain, muscle, and liver, with approxi-
mately 80% similarity between the muscle and liv-
er (15). The brain isoform is substantially diff erent 
and can be distinguished with an appropriate sen-
sitive immunoassay method (15). However, the 
magnitude of fl uctuation, depending on the initial 
concentration and clinical symptoms, is increas-
ingly important to diff erentiate between acute or 
chronic myocardial damage, which has been re-
ported recently for cTnI (6); however, the levels 
from baseline are still debated (1,2). The results 
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presented in this study show statistically signifi -
cant changes in the concentrations of H-FABP and 
GPBB as compared to their initial values (relative 
increase) at 3 h after the admission of AMI patients. 
This highlights the importance of H-FABP and 
GPBB for the early diagnosis of AMI. However, the 
sensitivities of H-FABP and GPBB in patients with 
AMI were relatively low at admission (approxi-
mately 40% for both markers), similarly to that 
showed during the fi rst hours after admission (33). 
However, they concomitantly increased, peaking 
at 3 h, before gradually decreasing by 20–40% at 
24 h. This emphasizes the rapidly changing dy-
namics of H-FABP and GPBB, owing to the narrow 
time period of their peak concentrations, relative 
increases and sensitivities, which highlights the 
importance of analyzing their concentrations 
throughout the fi rst 24 h of AMI onset. At 24 h, the 
sensitivity of GPBB was almost twice lower that of 
H-FABP, according the results shown herewith. 
Furthermore, GPBB has approximately twice lower 
relative increase then H-FABP during the fi rst 24 
hours after admission in patients having coronary 
chest pain for < 3 h, what one should keep in mind 
during the diagnosis of AMI. In our opinion there is 
no major benefi t to the simultaneous use of H-
FABP and GPBB because of their quite similar diag-
nostic accuracy up to the 24-h time point and be-
cause of the cost of such combined diagnostic ap-
proach.
In conclusion, our results show that H-FABP and 
GPBB can improve the early detection of AMI, with 
a high diagnostic accuracy. These biomarkers are 
especially useful for distinguishing between AMI 
and UA within 3 h after admission in patients with 
chest pain for < 3 hours, which is the time period 
during which an emergency physician should plan 
an objective cardiac ischaemia evaluation and ap-
propriate therapy.
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Dijagnostička točnost srčanog proteina koji veže masne kiseline (H-FABP) i 
BB izoenzima glikogen-fosforilaze (GPBB) u u postavljanju dijagnoze akutnog 
infarkta miokarda kod bolesnika s akutnim koronarnim sindromom
Sažetak
Uvod: Cilj ovog istraživanja je procijeniti mogu li se srčani protein koji veže masne kiseline (engl. heart fatty acid-binding protein, H-FABP) i BB 
izoenzim glikogen-fosforilaze (engl. glycogen phosphorylase isoenzyme BB, GPBB) rabiti za točno dijagnosticiranje akutnog infarkta miokarda 
(engl. acute myocardial infarction, AMI) kod bolesnika s akutnim koronarnim sindromom (engl. acute coronary syndrome, ACS).
Materijali i metode: U istraživanje je bilo uključeno 108 bolesnika s ACS primljenih na kardiološki odjel unutar 3 sata od pojave boli u prsima. 
Klasičnom metodom za određivanje koncentracije srčanog troponina I (cTnI) odvojili smo bolesnike s AMI i one s nestabilnom anginom (engl. un-
stabile angina, UA). Koncentracije H-FABP i GPBB određene su ELISA metodom pri prijemu (0 h) i 3, 6, 12 te 24 sati nakon prijema na odjel; njihova 
točnost kod postavljanja dijagnoze AMI procijenjena je statističkim metodama.
Rezultati: Od 92 bolesnika s ACS, 71 je imao AMI. Vršne vrijednosti koncentracija H-FABP i GPBB 3 sata nakon prijema bile su više od onih cTnI (P 
= 0,001). Nakon 24 sata oba su se biljega normalizirala. Područje ispod ROC krivulje bilo je značajno veće za oba biljega kod bolesnika s AMI nego 
kod bolesnika s UA u svim trenucima testiranja, uključujući i vrijeme prijema (P < 0,001). Kod prijema su osjetljivost za H-FABP (37%) i za GPBB 
(40%) bile relativno niske. Porasle su 3 i 6 sati nakon prijema za oba biljega, a nakon 24h su ponovno pale te iznosile 40% za H-FABP i približno 2 
puta niže za GPBB (P < 0,01). Kod bolesnika s AMI oba su biološka biljega imala slične specifi čnosti, pozitivne i negativne prediktivne vrijednosti, 
pozitivne i negativne omjere vjerojatnosti te omjere rizika za AMI.
Zaključak: Određivanje koncentracije H-FABP i GPBB može doprinijeti ranom dijagnosticiranju AMI te se može rabiti za razlikovanje AMI od UA.
Ključne riječi: biološki biljezi; srčani protein koji veže masne kiseline; glikogen-fosforilaza; osjetljivost; specifi čnost; akutni infarkt miokarda
